

# In vivo and in vitro sensitivity of Blastic Plasmacytoid Dendritic Cell Neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

## Treatment


Biological agent SL-401:  
recombinant IL-3 fused  
to diphtheria toxin

Other chemotherapeutic  
drugs

Biological agent SL-401:  
recombinant IL-3 fused  
to diphtheria toxin

Blastic Plasmacytoid Dendritic  
Cell Neoplasm (BPDCN)

### *in vitro* model



Cell lines or primary cells from patients

### *in vivo* model

NSG mice inoculated with  
BPDCN IL-3R<sup>+++</sup> cell line



## Response

